The U.S. Senate voted to block military action against Iran unless President Trump secures congressional authorization.

CSC Financial says the securities sector is in a convergence window of high earnings growth, low valuations and accelerating structural trends. Earnings: strong interim results plus conversion of investment‑banking deal flow provide ongoing validation. Industry: consolidation in large-scale wealth-management, scaling of sci‑tech investment‑banking capabilities and faster international expansion underpin a higher medium-to-long-term earnings baseline. Valuation: PB at historically low percentiles offers a margin of safety. Against rising trade overcrowding in technology and capital rotating from high- to low-valuation areas, the sector’s risk/reward profile remains attractive.

Tianfang Pharmaceutical, a unit of Tongyong Technology China Pharmaceuticals, received an NMPA supplemental-approval notice for diclofenac sodium enteric-coated tablets after passing generic quality and efficacy consistency evaluation. Indications include inflammatory and degenerative rheumatic diseases, non-articular soft-tissue rheumatic pain, acute mild-to-moderate pain and acute gout attacks. The product is listed on China’s national reimbursement list (Category A).